Medicaid Final Rule FR-2026-16508: Federal Funding Ban — Update State Plans by October 13
FR-2026-16508 prohibits federal Medicaid and CHIP matching payments for sex-rejecting procedures in minors effective October 13, 2026, with a 6-month hormone therapy transition.
Action required by
October 13, 2026
Review the Action Required section below and ensure your team has completed all compliance steps before this date.
Final Rule FR-2026-16508, published August 13, 2026 in the Federal Register, adds a new subpart N to 42 CFR part 441 (Medicaid) and revises subpart D of 42 CFR part 457 (CHIP), prohibiting the use of federal financial participation (FFP) for sex-rejecting procedures furnished to Medicaid beneficiaries under age 18 and CHIP beneficiaries under age 19. The rule is effective October 13, 2026. The single most critical compliance implication: State Medicaid and CHIP agencies must amend their federally approved State plans to reflect this prohibition before the effective date, or risk losing FFP on any claims for these procedures after October 13, 2026.
Regulatory Background
Sign in to read the full article
Create a free account to access the complete analysis, action recommendations, and related alert references.
Quick answers
Does the 6-month hormone therapy transition provision in FR-2026-16508 apply to all hormone therapy claims, or only to beneficiaries already actively receiving cross-sex hormone therapy on October 13, 2026?
The transition provision is limited to beneficiaries who are actively receiving cross-sex hormone therapy at the time the rule takes effect on October 13, 2026. States may claim FFP for those specific hormone therapy medications for up to 6 months from the effective date — through no later than April 13, 2027. New initiations of cross-sex hormone therapy on or after October 13, 2026 would not qualify for the transition window and would be subject to the FFP prohibition.
If our State is one of the plaintiff States covered by the preliminary injunctions in Washington v. Trump or PFLAG, Inc. v. Trump, does FR-2026-16508 still apply?
CMS states in the final rule that FR-2026-16508 does not conflict with the existing preliminary injunctions because it is based on independent legal authority — specifically sections 1902(a)(19) and 1902(a)(30)(A) of the Social Security Act and section 5(a) of EO 14187 — rather than the enjoined sections of EO 14168 or EO 14187. However, the rule also notes it will not be implemented in contravention of any court orders. Compliance officers in plaintiff States should obtain written legal guidance before modifying claims processing or State plan language, as the interaction between this final rule and the existing injunctions may be subject to further litigation.
Does FR-2026-16508 prevent States from covering sex-rejecting procedures for minors using State-only funds?
No. The final rule explicitly states that these changes do not prevent States from providing coverage for sex-rejecting procedures using State-only funds outside the federally matched Medicaid program or CHIP, and do not restrict private insurance coverage. The prohibition applies solely to the use of federal FFP (FMAP for Medicaid, enhanced FMAP for CHIP) for these procedures.
Content summarized from publicly available federal publications including CMS, MAC contractors, and the Federal Register. CLV Intelligence is not affiliated with or endorsed by any government agency. This is not legal or medical advice.